

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

Market Report | 2022-08-03 | 210 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The cell therapy technologies market is projected to reach USD 8.0 Billion by 2027 from USD 4.0 Billion in 2022, at a CAGR of 14.6% during the forecast period. The growth can be attributed to the increasing public-private partnerships. Several government and private organizations have made significant investments to strengthen R&D in cell therapy leading to surge in cell therapy technologies demand, hence propelling market growth.

"The cell preservation and distribution and handling process segment accounted for the second largest share of the market in 2021"

Cell preservation and distribution is an essential and vital step in the cell scaling-up process. In addition, with the growth in the demand for cell-based medical products and therapies, the demand for reliable storage equipment to preserve finite cell lines and cells manufactured in excess is expected to increase. This factor is expected to drive the growth of this market segment.

"The CROs and CMOs accounted for the second largest share of the cell therapy technologies market in 2021"

To cater the large demand, pharmaceutical companies need to speed up clinical timelines, maintain business continuity, and free up resources for projects. This has increased outsourcing analytical tests to CROs and CMOs, thereby boosting the segment market growth.

Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US), are some of the major players operating in the market.

"Asia Pacific: The fastest-growing region in the cell therapy technologies market"

The Asia Pacific market is expected to register the highest CAGR during the forecast period. Some of the major factors contributing to the growth of the Asia Pacific market are low-cost manufacturing advantage, increasing per capita income, and growing need to curb cancer. In addition, the growth of geriatric population is also fueling the cell therapy technologies market in the region.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 80% and Demand Side - 20%
- By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
- By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:

- Thermo Fisher Scientific, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Lonza Group (Switzerland)
- Sartorius AG (Germany)
- Terumo BCT (US)
- Becton, Dickinson and Company (US)
- Fresenius SE & Co. KGaA (Germany)
- Avantor, Inc. (US)
- Bio-Techne Corporation (US)
- Corning Incorporated (US)
- FUJIFILM Irvine Scientific (US)
- MaxCyte Inc. (US)
- Werum IT Solutions GmbH (Germany)
- RoosterBio Inc. (US)
- SIRION Biotech GmbH (Germany)
- TrakCel (UK)
- L7 Informatics, Inc. (US)
- Miltenyi Biotec GmbH (Germany)
- STEMCELL Technologies (Canada)
- GPI Iberia (Spain)
- MAK-SYSTEM (US), OrganaBio, LLC (US)
- IxCells Biotechnology (China)
- Wilson Wolf Manufacturing Corporation (US)

Research Coverage:

This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments such as the product, process, cell type, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

Table of Contents:

1 INTRODUCTION 31

1.1 STUDY OBJECTIVES 31

1.2 MARKET DEFINITION 31

1.2.1 INCLUSIONS AND EXCLUSIONS 32

1.3 MARKET SCOPE 32

1.3.1 MARKETS COVERED 32

FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION 32

1.3.2 YEARS CONSIDERED 33

1.4 CURRENCY CONSIDERED 33

1.5 LIMITATIONS 33

1.6 STAKEHOLDERS 34

1.7 SUMMARY OF CHANGES 34

2 RESEARCH METHODOLOGY 35

2.1 RESEARCH DATA 35

FIGURE 2 RESEARCH DESIGN 35

2.1.1 SECONDARY DATA 36

2.1.2 PRIMARY DATA 36

FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: CELL THERAPY TECHNOLOGIES MARKET 37

2.2 MARKET ESTIMATION METHODOLOGY 38

FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021 38

FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 38

2.2.1 INSIGHTS FROM PRIMARY EXPERTS 39

FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 39

2.3 MARKET GROWTH RATE PROJECTIONS 40

FIGURE 7 CELL THERAPY TECHNOLOGIES MARKET (SUPPLY SIDE): CAGR PROJECTIONS 41

FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 42

2.4 DATA TRIANGULATION 43

FIGURE 9 DATA TRIANGULATION METHODOLOGY 43

2.5 RESEARCH ASSUMPTIONS 44

2.6 RISK ANALYSIS 44

3 EXECUTIVE SUMMARY 45

FIGURE 10 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 45

FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022 VS. 2027 (USD MILLION) 46

FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION) 46

FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 47

FIGURE 14 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET 48

4 PREMIUM INSIGHTS 49

4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 49

FIGURE 15 INCREASING GOVERNMENT INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH 49

4.2 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SHARE, BY CELL TYPE AND COUNTRY (2021) 50

FIGURE 16 T CELLS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 50

4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2022 VS. 2027 50

FIGURE 17	MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2027	50
4.4	CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PROCESS, 2022	51
FIGURE 18	CELL PROCESSING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022	51
4.5	CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	51
FIGURE 19	ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD	51
5	MARKET OVERVIEW	52
5.1	INTRODUCTION	52
5.2	MARKET DYNAMICS	52
FIGURE 20	CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	52
5.2.1	DRIVERS	53
5.2.1.1	Increasing government investments in cell-based research	53
TABLE 1	NIH FUNDING FOR CELL-BASED RESEARCH, 2016-2019 (USD MILLION)	53
5.2.1.2	Rising incidence of chronic and infectious diseases	54
5.2.1.3	Large number of oncology-related cell therapy clinical trials	54
FIGURE 21	CANCER CELL THERAPY PIPELINE (MARCH 2019-MARCH 2020)	55
5.2.1.4	Increasing GMP certifications for cell therapy production facilities	55
TABLE 2	EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP	55
5.2.2	RESTRAINTS	56
5.2.2.1	High cost of cell-based research and low success rate	56
TABLE 3	COST OF CELL THERAPY EQUIPMENT	56
5.2.2.2	Dearth of skilled professionals	56
5.2.3	OPPORTUNITIES	57
5.2.3.1	Emergence of iPSCs as alternatives to ESCs	57
5.2.3.2	Increased focus on personalized medicine	57
5.2.3.3	Increasing public-private partnerships for development of cell therapies	58
5.2.3.4	Emerging Asian markets	58
5.2.4	CHALLENGES	58
5.2.4.1	Survival of small players and new entrants	58
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	59
FIGURE 22	REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS	59
5.4	INDICATIVE PRICING MODEL ANALYSIS	59
TABLE 4	PRICING ANALYSIS OF CELL THERAPY PRODUCTS	59
5.5	TECHNOLOGY ANALYSIS	60
5.6	VALUE CHAIN ANALYSIS	60
FIGURE 23	VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE	60
5.7	SUPPLY CHAIN ANALYSIS	61
FIGURE 24	CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS	62
5.8	ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET	62
FIGURE 25	ECOSYSTEM ANALYSIS	62
TABLE 5	SUPPLY CHAIN ECOSYSTEM	63
5.9	KEY CONFERENCES AND EVENTS IN 2022-2023	64
TABLE 6	CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS	64
5.10	REGULATORY ANALYSIS	65
5.10.1	NORTH AMERICA	65
TABLE 7	NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES	65
5.10.2	EUROPE	66
TABLE 8	EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES	66

5.10.3 ASIA PACIFIC 67

TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES 67

5.10.4 REST OF THE WORLD 68

TABLE 10 REST OF THE WORLD: REGULATORY LANDSCAPE FOR CELL THERAPIES 68

5.11 PORTER'S FIVE FORCES ANALYSIS 69

TABLE 11 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS 69

5.11.1 THREAT OF NEW ENTRANTS 69

5.11.2 THREAT OF SUBSTITUTES 69

5.11.3 BARGAINING POWER OF SUPPLIERS 69

5.11.4 BARGAINING POWER OF BUYERS 69

5.11.5 DEGREE OF COMPETITION 69

5.12 PATENT ANALYSIS 70

FIGURE 26 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JANUARY 2012-JULY 2022 70

TABLE 12 INDICATIVE LIST OF PATENTS IN CELL THERAPY TECHNOLOGIES MARKET 70

5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 71

5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 71

FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF CELL THERAPY PRODUCTS 71

5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS 72

FIGURE 28 KEY BUYING CRITERIA FOR END USERS 72

6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 73

6.1 INTRODUCTION 74

TABLE 13 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 74

6.2 MEDIA, SERA, AND REAGENTS 74

6.2.1 MEDIA, SERA, AND REAGENTS ARE INTEGRAL PARTS OF CELL PROCESSING 74

TABLE 14 CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY REGION, 2020-2027 (USD MILLION) 75

TABLE 15 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION) 75

TABLE 16 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION) 75

TABLE 17 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION) 76

6.3 CELL ENGINEERING PRODUCTS 76

6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS SUPPORTS MARKET GROWTH 76

TABLE 18 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 76

TABLE 19 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 77

TABLE 20 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 77

TABLE 21 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 77

6.4 CELL CULTURE VESSELS 78

6.4.1 CELL CULTURE VESSELS ARE WIDELY USED FOR CELL GROWTH 78

TABLE 22 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY REGION, 2020-2027 (USD MILLION) 78

TABLE 23 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 24 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020-2027 (USD MILLION) 79

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 25 □ ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020-2027 (USD MILLION) □79

6.5 □ EQUIPMENT □79

TABLE 26 □ CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY REGION, 2020-2027 (USD MILLION) □80

TABLE 27 □ NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □80

TABLE 28 □ EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □80

TABLE 29 □ ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □81

TABLE 30 □ CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY TYPE, 2020-2027 (USD MILLION) □81

6.5.1 □ CELL PROCESSING EQUIPMENT □81

6.5.1.1 □ Cell processing equipment segment dominates cell therapy equipment market □81

TABLE 31 □ CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY REGION, 2020-2027 (USD MILLION) □82

TABLE 32 □ NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □82

TABLE 33 □ EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □82

TABLE 34 □ ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □83

6.5.2 □ SINGLE-USE EQUIPMENT □83

6.5.2.1 □ Benefits of single-use equipment have ensured end-user demand □83

TABLE 35 □ CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY REGION, 2020-2027 (USD MILLION) □83

TABLE 36 □ NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □84

TABLE 37 □ EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □84

TABLE 38 □ ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □84

6.5.3 □ OTHER EQUIPMENT □85

TABLE 39 □ CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY REGION, 2020-2027 (USD MILLION) □85

TABLE 40 □ NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □85

TABLE 41 □ EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □86

TABLE 42 □ ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION) □86

6.6 □ SYSTEMS AND SOFTWARE □86

6.6.1 □ SYSTEMS AND SOFTWARE ARE USED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING □86

TABLE 43 □ CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY REGION, 2020-2027 (USD MILLION) □87

TABLE 44 □ NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION) □87

TABLE 45 □ EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION) □87

TABLE 46 □ ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION) □88

?

6.7 □ OTHER PRODUCTS □88

TABLE 47 □ CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY REGION, 2020-2027 (USD MILLION) □88

TABLE 48 □ NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) □89

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 49	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION)	89
TABLE 50	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION)	89
7	CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS	90
7.1	INTRODUCTION	91
TABLE 51	CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	91
7.2	CELL PROCESSING	91
7.2.1	CELL PROCESSING MAKES WIDE USE OF CELL THERAPY INSTRUMENTS	91
TABLE 52	CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2020-2027 (USD MILLION)	91
TABLE 53	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020-2027 (USD MILLION)	92
TABLE 54	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020-2027 (USD MILLION)	92
TABLE 55	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020-2027 (USD MILLION)	92
7.3	CELL PRESERVATION, DISTRIBUTION, AND HANDLING	93
7.3.1	INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH	93
TABLE 56	CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2020-2027 (USD MILLION)	93
TABLE 57	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020-2027 (USD MILLION)	93
TABLE 58	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020-2027 (USD MILLION)	94
TABLE 59	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020-2027 (USD MILLION)	94
7.4	PROCESS MONITORING AND QUALITY CONTROL	95
7.4.1	PROCESS MONITORING IS ESSENTIAL TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING	95
TABLE 60	CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2020-2027 (USD MILLION)	95
TABLE 61	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020-2027 (USD MILLION)	96
TABLE 62	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020-2027 (USD MILLION)	96
TABLE 63	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020-2027 (USD MILLION)	96
8	CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE	97
8.1	INTRODUCTION	98
TABLE 64	CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	98
8.2	T CELLS	98
8.2.1	RESEARCH CONDUCTED ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH	98
TABLE 65	CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2020-2027 (USD MILLION)	99
TABLE 66	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	99
TABLE 67	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	99
TABLE 68	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	100
8.3	STEM CELLS	100
8.3.1	INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE SEGMENT GROWTH	100
TABLE 69	CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2020-2027 (USD MILLION)	101
TABLE 70	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	101

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 71	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	101
TABLE 72	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	102
8.4	OTHER CELLS	102
TABLE 73	CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2020-2027 (USD MILLION)	102
TABLE 74	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	103
TABLE 75	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	103
TABLE 76	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020-2027 (USD MILLION)	103
9	CELL THERAPY TECHNOLOGIES MARKET, BY END USER	104
9.1	INTRODUCTION	105
TABLE 77	CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	105
9.2	BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES	105
9.2.1	RIISING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE SEGMENT GROWTH	105
TABLE 78	CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)	106
TABLE 79	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)	106
TABLE 80	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)	106
TABLE 81	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)	107
9.3	CROS AND CMOS	107
9.3.1	RIISING FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH	107
TABLE 82	CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY REGION, 2020-2027 (USD MILLION)	107
TABLE 83	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020-2027 (USD MILLION)	108
TABLE 84	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020-2027 (USD MILLION)	108
TABLE 85	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020-2027 (USD MILLION)	108
9.4	RESEARCH INSTITUTES AND CELL BANKS	109
9.4.1	MARKET GROWTH IS SUPPORTED BY RIISING RESEARCH ACTIVITY	109
TABLE 86	CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2020-2027 (USD MILLION)	109
TABLE 87	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020-2027 (USD MILLION)	109
TABLE 88	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020-2027 (USD MILLION)	110
TABLE 89	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020-2027 (USD MILLION)	110
10	CELL THERAPY TECHNOLOGIES MARKET, BY REGION	111
10.1	INTRODUCTION	112
TABLE 90	CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2020-2027 (USD MILLION)	112
10.2	NORTH AMERICA	112
FIGURE 29	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT	113
TABLE 91	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	113
TABLE 92	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	114
TABLE 93	NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	114

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 94	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	114
TABLE 95	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	115
TABLE 96	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	115
10.2.1	US	115
10.2.1.1	Increasing R&D activities to support market growth	115
TABLE 97	US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	116
TABLE 98	US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	116
TABLE 99	US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	116
TABLE 100	US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	117
TABLE 101	US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	117
10.2.2	CANADA	117
10.2.2.1	Increasing government funding to drive adoption of cell therapy instruments	117
TABLE 102	CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	118
TABLE 103	CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	118
TABLE 104	CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	118
TABLE 105	CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	119
TABLE 106	CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	119
10.3	EUROPE	119
TABLE 107	EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	120
TABLE 108	EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	120
TABLE 109	EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	120
TABLE 110	EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	121
TABLE 111	EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	121
TABLE 112	EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	121
10.3.1	GERMANY	122
10.3.1.1	Germany holds largest share of European market	122
TABLE 113	GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	122
TABLE 114	GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	122
TABLE 115	GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	123
TABLE 116	GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	123
TABLE 117	GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	123
10.3.2	UK	124
10.3.2.1	Favorable funding and investment scenario to drive market growth	124
TABLE 118	UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	124
TABLE 119	UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	124
TABLE 120	UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	125
TABLE 121	UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	125
TABLE 122	UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	125
10.3.3	FRANCE	126
10.3.3.1	Availability of government and private support to drive market growth	126
TABLE 123	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	126
TABLE 124	FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	127
TABLE 125	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	127
TABLE 126	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	127
TABLE 127	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	128
10.3.4	ITALY	128
10.3.4.1	Initiatives favoring cell and gene therapy development to support market growth	128

TABLE 128	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	129
TABLE 129	ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	129
TABLE 130	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	129
TABLE 131	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	130
TABLE 132	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	130
10.3.5	SPAIN	130
10.3.5.1	Increasing funding from private and public organizations to aid market growth	130
TABLE 133	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	131
TABLE 134	SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	131
TABLE 135	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	131
TABLE 136	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	132
TABLE 137	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	132
10.3.6	REST OF EUROPE	132
TABLE 138	ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	133
TABLE 139	ROE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	133
TABLE 140	ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	133
TABLE 141	ROE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	134
TABLE 142	ROE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	134
10.4	ASIA PACIFIC	134
FIGURE 30	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT	135
TABLE 143	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	135
TABLE 144	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	136
TABLE 145	ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	136
TABLE 146	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	136
TABLE 147	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	137
TABLE 148	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	137
10.4.1	CHINA	137
10.4.1.1	Increasing cell therapy-based trials to support market growth	137
TABLE 149	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	138
TABLE 150	CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	138
TABLE 151	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	138
TABLE 152	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	139
TABLE 153	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	139
10.4.2	JAPAN	139
10.4.2.1	Rising geriatric population and growing disease prevalence to drive market growth	139
TABLE 154	JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025	140
TABLE 155	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	140
TABLE 156	JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	140
TABLE 157	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	141
TABLE 158	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	141
TABLE 159	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	141
10.4.3	INDIA	142
10.4.3.1	Favorable government regulations to support market growth	142
TABLE 160	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	142
TABLE 161	INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	142
TABLE 162	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	143
TABLE 163	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	143

TABLE 164	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	143
10.4.4	REST OF ASIA PACIFIC	144
TABLE 165	ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	144
TABLE 166	ROAPAC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	144
TABLE 167	ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	145
TABLE 168	ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	145
TABLE 169	ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	145
10.5	LATIN AMERICA	146
10.5.1	AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET GROWTH	146
TABLE 170	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	146
TABLE 171	LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	146
TABLE 172	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	147
TABLE 173	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	147
TABLE 174	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	147
10.6	MIDDLE EAST AND AFRICA	148
10.6.1	INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET GROWTH	148
TABLE 175	MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	148
TABLE 176	MIDDLE EAST AND AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)	148
TABLE 177	MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020-2027 (USD MILLION)	149
TABLE 178	MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020-2027 (USD MILLION)	149
TABLE 179	MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020-2027 (USD MILLION)	149
11	COMPETITIVE LANDSCAPE	150
11.1	INTRODUCTION	150
11.2	RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS	150
FIGURE 31	CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED	151
11.3	MARKET SHARE ANALYSIS	152
FIGURE 32	CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)	152
TABLE 180	CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION	152
11.4	REVENUE ANALYSIS	153
FIGURE 33	REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)	153
11.5	COMPANY EVALUATION MATRIX	154
FIGURE 34	CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX, 2021	154
11.5.1	STARS	155
11.5.2	EMERGING LEADERS	155
11.5.3	PERVASIVE PLAYERS	155
11.5.4	PARTICIPANTS	155
11.6	COMPANY EVALUATION MATRIX: START-UPS/SMES	156
FIGURE 35	CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021	156
11.6.1	PROGRESSIVE COMPANIES	157
11.6.2	STARTING BLOCKS	157
11.6.3	RESPONSIVE COMPANIES	157
11.6.4	DYNAMIC COMPANIES	157
11.6.5	COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS	157
TABLE 181	CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UPS/SMES	157
TABLE 182	CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES	159
11.7	COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS	159
11.7.1	COMPANY FOOTPRINT (25 COMPANIES)	159

TABLE 183	COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS	159
11.7.2	PRODUCT FOOTPRINT (25 COMPANIES)	160
TABLE 184	PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS	160
11.7.3	PROCESS FOOTPRINT (25 COMPANIES)	161
TABLE 185	PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS	161
11.7.4	REGIONAL FOOTPRINT (25 COMPANIES)	162
TABLE 186	REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS	162
11.8	COMPETITIVE SCENARIO AND TRENDS	163
11.8.1	PRODUCT LAUNCHES	163
TABLE 187	CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES (JANUARY 2019-JULY 2022)	163
11.8.2	DEALS	164
TABLE 188	CELL THERAPY TECHNOLOGIES MARKET: DEALS (JANUARY 2019-JULY 2022)	164
11.8.3	OTHER DEVELOPMENTS	164
TABLE 189	CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS (JANUARY 2019-JULY 2022)	164
12	COMPANY PROFILES	165
12.1	KEY PLAYERS	165
	(Business Overview, Products Offered, Recent Developments, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats)*	
12.1.1	THERMO FISHER SCIENTIFIC, INC.	165
TABLE 190	THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW	165
FIGURE 36	THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT	166
12.1.2	MERCK KGAA	170
TABLE 191	MERCK KGAA: BUSINESS OVERVIEW	170
FIGURE 37	MERCK KGAA: COMPANY SNAPSHOT	171
12.1.3	DANAHER CORPORATION	174
TABLE 192	DANAHER CORPORATION: BUSINESS OVERVIEW	174
FIGURE 38	DANAHER CORPORATION: COMPANY SNAPSHOT	175
12.1.4	LONZA GROUP	179
TABLE 193	LONZA GROUP: BUSINESS OVERVIEW	179
FIGURE 39	LONZA GROUP: COMPANY SNAPSHOT	180
12.1.5	SARTORIUS AG	182
TABLE 194	SARTORIUS AG: BUSINESS OVERVIEW	182
FIGURE 40	SARTORIUS AG: COMPANY SNAPSHOT	183
12.1.6	TERUMO BCT, INC.	185
TABLE 195	TERUMO CORPORATION: BUSINESS OVERVIEW	185
FIGURE 41	TERUMO CORPORATION: COMPANY SNAPSHOT	185
12.1.7	BECTON, DICKINSON AND COMPANY	187
TABLE 196	BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW	187
FIGURE 42	BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT	188
12.1.8	FRESENIUS SE & CO. KGAA	189
TABLE 197	FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW	189
FIGURE 43	FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT	189
12.1.9	AVANTOR, INC.	191
TABLE 198	AVANTOR, INC.: BUSINESS OVERVIEW	191
FIGURE 44	AVANTOR, INC.: COMPANY SNAPSHOT	192
12.1.10	BIO-TECHNE CORPORATION	194
TABLE 199	BIO-TECHNE CORPORATION: BUSINESS OVERVIEW	194

FIGURE 45 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT 195

12.1.11 CORNING INCORPORATED 198

TABLE 200 CORNING INCORPORATED: BUSINESS OVERVIEW 198

FIGURE 46 CORNING INCORPORATED: COMPANY SNAPSHOT 199

12.1.12 FUJIFILM IRVINE SCIENTIFIC 200

TABLE 201 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW 200

FIGURE 47 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT 201

12.1.13 MAXCYTE, INC. 202

TABLE 202 MAXCYTE: BUSINESS OVERVIEW 202

FIGURE 48 MAXCYTE: COMPANY SNAPSHOT 202

*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

12.2 OTHER PLAYERS 204

12.2.1 WERUM IT SOLUTIONS 204

12.2.2 ROOSTERBIO, INC. 204

12.2.3 SIRION BIOTECH GMBH 205

12.2.4 TRAKCEL 205

12.2.5 L7 INFORMATICS 206

12.2.6 MILTENYI BIOTEC 206

12.2.7 STEMCELL TECHNOLOGIES INC. 207

12.2.8 GPI IBERIA (FORMERLY HEMASOFT) 209

12.2.9 MAK-SYSTEM 209

12.2.10 ORGANABIO, LLC 210

12.2.11 IXCELLS BIOTECHNOLOGIES 210

12.2.12 WILSON WOLF MANUFACTURING CORPORATION 211

13 APPENDIX 212

13.1 DISCUSSION GUIDE 212

13.2 KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL 215

13.3 CUSTOMIZATION OPTIONS 217

13.4 RELATED REPORTS 217

13.5 AUTHOR DETAILS 218

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

Market Report | 2022-08-03 | 210 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>